FIELD: medicine; neuropathology. SUBSTANCE: haloperilol is administered to patient in daily dose 0.75-1.5 mg, and, additionally, cubital fossae of both arms are alternately subjected to laser-magnetic irradiation emitted by MILTA apparatus with power up to 4 Wt, for 3-7 min., one a day, treatment course including 7-12 therapeutic sessions. EFFECT: enhanced therapeutic efficiency. 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING PATIENTS SUFFERING FROM CHRONIC ARTERIAL INSUFFICIENCY OF LOWER EXTREMITIES | 2000 |
|
RU2162356C1 |
METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | 2002 |
|
RU2216328C1 |
ANTIBACTERIAL AGENT | 1999 |
|
RU2157686C1 |
METHOD OF PSYCHOTHERAPEUTIC IMPACT | 1999 |
|
RU2179038C2 |
MEANS FOR TREATING INSULIN RESISTANCE | 1999 |
|
RU2158590C1 |
AGENT FOR TICOSIS HYPERKINESIS TREATMENT | 1995 |
|
RU2099079C1 |
METHOD FOR TREATING ENURESIS IN CHILDREN | 1999 |
|
RU2141305C1 |
METHOD OF HUMAN ORGANISM ADAPTATION IN PATHOLOGICAL PROCESSES ACCOMPANYING WITH METABOLIC DISORDERS | 1996 |
|
RU2132192C1 |
METHOD FOR TREATING INFLAMMATORY INFECTION DISEASES OF MALE REPRODUCTIVE SYSTEM ORGANS | 1995 |
|
RU2087152C1 |
METHOD FOR TREATING BOTULISM | 1995 |
|
RU2119799C1 |
Authors
Dates
1997-10-10—Published
1994-04-06—Filed